P21 (CNTF-Derived Peptide) Evidence Guide
Evidence for P21 Peptide is too preliminary to support a research protocol with confidence. Published data is extremely limited - a handful of in vitro and rodent studies, with no human pharmacokinetic data or clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has vastly more clinical evidence as a starting point.
Our Take
Evidence for P21 Peptide is too preliminary to support a research protocol with confidence. Published data is extremely limited - a handful of in vitro and rodent studies, with no human pharmacokinetic data or clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has vastly more clinical evidence as a starting point.
- Best for
- CNTF pathway mechanistic research (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Hippocampal Neurogenesis: Level D, mostly non-human evidence - P21 treatment significantly increased BrdU-positive neurons in the dentate gyrus of aged mice and AD transgenic models, indicating robust promotion of adult neurogenesis.
- Tau Pathology Reduction: Level D, mostly non-human evidence - In 3xTg-AD mice, chronic P21 treatment reduced hyperphosphorylated tau at multiple epitopes and improved performance in Morris water maze tasks.
- Spatial Memory: Level D, mostly non-human evidence - Both aged wild-type and AD-model mice showed improved spatial learning and memory retention following P21 treatment in water maze and object recognition paradigms.
Side Effects and Warnings
- No significant adverse effects reported in animal studies
- Potential unknown risks in humans
- No human trials have been conducted
- Long-term effects of chronic neurogenesis stimulation are unknown
- Theoretical risk of promoting uncontrolled cell proliferation
Research Dosage References
- <strong>Oral gavage (animal studies)</strong> - 60 nmol/g diet - Continuous in feed - P21 is orally bioavailable with demonstrated brain penetration in rodent studies. No human doses established.
Mechanism of Action
P21 increases BDNF expression by enhancing CREB phosphorylation through a CNTF receptor-independent mechanism. It promotes dentate gyrus neurogenesis by stimulating neural progenitor cell proliferation and differentiation. Concurrently, P21 inhibits leukemia inhibitory factor (LIF) signaling, which reduces GSK-3beta activation, thereby decreasing tau hyperphosphorylation at key AD-related epitopes (Ser202, Thr205, Ser396). The net effect is enhanced synaptic plasticity and reduced tau pathology.
Legal Status
Research compound only; not available for human use.
Primary Sources
- A small peptide with a potent effect on neurogenesis and cognitive function in aged mice. Neurobiology of Aging, 2014.
- An orally bioavailable CNTF-derived peptide reduces tau pathology and improves cognition in AD mice. Journal of Alzheimer's Disease, 2016.
Popular Questions
- P21 (CNTF-Derived Peptide) Benefits: Evidence, Verdict, and Limits
- P21 (CNTF-Derived Peptide) Side Effects: Safety Signals and Warnings
- P21 (CNTF-Derived Peptide) Research Dosage: Published Protocol Reference
- Is P21 (CNTF-Derived Peptide) Legit? Evidence Grade and Plain-English Verdict
- P21 (CNTF-Derived Peptide) Legal Status: Approval, Research Use, and Regulatory Notes